Castle Biosciences, Inc. (CSTL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 63 | 94 | 137 | 220 | 332 | 344 | 357 | 373 |
| Operating profit | $m | -43 | -32 | ||||||
| Net profit | $m | -10 | -31 | -67 | -57 | 18 | -24 | -19 | -37 |
| EPS reported | $ | -0.83 | -0.66 | ||||||
| Operating cashflow per share | $ | 2.22 | 1.40 | ||||||
| Capex per share | $ | 1.24 | 1.42 | ||||||
| FCF per share | $ | 0.98 | -0.02 | ||||||
| Free cash flow | $m | 28 | -0 | ||||||
| Net debt | $m | -289 | -257 | ||||||
| Book value equity | $m | 471 | 470 | ||||||
| Book value per share | $ | 16.24 | 15.46 | ||||||
| Number of shares | m | 28.99 | 30.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.39 | 2.40 | ||||||
| P/S LTM | x | 3.28 | 3.16 | ||||||
| P/FCF LTM | x | 39.81 | -2,305.84 | ||||||
| EV/EBITDA LTM | x | 92.37 | -323.78 | ||||||
| EV/Sales LTM | x | 3.04 | 2.74 | ||||||
| Earnings Yield LTM | % | -2.14% | -1.94% | ||||||
| FCF Yield | % | +2.51% | -0.04% | ||||||
| Quality | |||||||||
| ROE | % | -5.13% | -4.15% | ||||||
| ROIC | % | -6.85% | -6.31% | ||||||
| Operating margin | % | -12.44% | -8.99% | ||||||
| Gross margin | % | +79.37% | +77.26% | ||||||
| FCF/Sales | % | +8.23% | -0.14% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +3.66% | +7.59% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -22.48% | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.77 | -0.01 | ||||||
| Net Debt/EBITDA | x | -7.04 | 7.87 | ||||||
| EBIT/Net interest | x | -497.79 | -85.62 | ||||||
| Net debt/market cap | % | +0.89% | +1.00% | ||||||
| Net debt/Equity | x | -0.61 | -0.55 | ||||||
| Gross debt/equity | x | 0.08 | 0.08 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free